In the United States, adolescent and young adult (AYA) patients with cancer have the lowest clinical trial participation rate of all age groups and slower progress in survival improvement than 
INTRODUCTION
In the United States, adolescent and young adult (AYA) patients with cancer have the lowest participation rate in clinical trials of all age groups, including infants and except for the most elderly (over 85 years of age). 1 Because acquisition of clinical specimens for translational research occurs primarily in the setting of clinical trials at academic medical centers, AYAs also have the lowest proportion of specimens available for laboratory and translational research. 2 
METHODS AND MATERIALS

Study cohorts
Incidence, mortality and survival data were obtained from the National Cancer Institute (NCI) Surveillance 
Statistical analysis
Relative survival was used to assess cancer mortality changes over time. Relative survival accounts for competing causes of death as the ratio of observed survival among patients with cancer to expected survival in the overall population of the same age as computed from life tables of mortality in the general population. 6 We obtained 5-year relative survival estimates with corresponding 95% confidence intervals (CI) using NCI SEER*Stat software program version 4.2.0.2. 
Highlights
• AYA patients with cancer in the United States have had since 1980 a slower rate of survival improvement and mortality reduction than those with cancer in younger and older age groups.
• Survival prolongation and mortality reduction in patients with cancer is directly correlated with clinical trial activity and apparent at all ages.
• AYA patients with cancer have had the lowest participation rate in clinical trials than any other age group.
• Even worse, AYAs have had, since 2010, a steady decline in accrual to treatment trials sponsored by National Cancer Institute.
• Moreover, clinical trial accruals have their all-age nadir at precisely the peak age prevalence of AYA cancers.
• The slower rate of survival improvement and mortality reduction is associated with, and a likely resultant of, their low participation rate in clinical trials and lack of tissue specimens for research.
• The problem is particularly obvious in 20-29 year olds with acute lymphoblastic leukemia, who have had little to no improvement in the 5-year survival rate since 1989.
• In order to reverse the accrual trend, multiple changes are necessary, including convincing community oncologists to pursue clinical trials on behalf of their AYA patients.
• Also the new National Cancer Treatment Network and National Community Oncology Research Program and the Food and Drug Administration should lead a coordinated attack to eliminate the accrual gap.
• Other solutions include broader health insurance availability for AYAs and coverage of clinical trials. Increased availability of clinical trials specifically for AYAs with cancer.
• Pediatric and adult oncologists should establish a mutual goal that was achieved in children to have clinical trials become a standard of care for AYA cancers. Figure 1A and 
RESULTS
National treatment trial accruals 1997-2015
Acute lymphoblastic leukemia since 2000
The greatest effort during the last decade to increase accruals in AYAs was directed at ALL, the most common pediatric cancer. New clinical trials in ALL specifically designed for AYAs were launched, [11] [12] [13] [14] the National Comprehensive Cancer Network (NCTN) released F I G U R E 2 A. Accruals to treatment trials sponsored by National Cancer Institute (NCI)-sponsored cooperative groups and NCIdesignated cancer centers (black curve) and proportion of all cancer accounted for by 14 cancers with peak age proportion during AYA years during (purple curve), 2000-2014, by single year of age. B. Ratio of accruals to proportion of the 14 cancers of all cancer (red curve). Accrual data source is the same as in Figure 1 . Data on the proportion of all cancer were obtained from incidence data for SEER 18 regions 3 and from the U.S. Census Bureau for population data 5 practice guidelines for ALL, 15 and an increasing number of presentations and publications on the topic occurred at national meetings and appeared in the peer-reviewed medical literature. Figure 1B 2010  1717  916  811  642  262  265  441  773  1348  2217  2773  3468  3420  2769  1758   2015  1151  790  693  579  162  170  210  358  599  955  1528  1854  2142  2239  1543 Change −33% −14% −15% −10% −38% −36% −52% −54% −56% −57% −45% −47% −37% −19% −12% Data source is the same as in Figure 1 . a Excluding AIDS-related entities. b Mean (95% confidence interval) of seven age groups between 26 and 64 years, the age range between CHIP and Medicare coverage. Among AYAs however, these trials are less common since AYAs have different cancers (Fig. 2) and, since they are a much smaller population than those of older age, fewer drugs are developed for them by the industry.
One explanation for the improvement in older adolescents is the cooperation between COG and the adult cooperative groups that study the overlapping AYA age range. In particular, the NCTN has formed a specific intergroup committee representing the AYA interests of the pediatric and adult cooperative groups. In addition, several of the adult cooperative groups have their own AYA committees focused on studying cancers prevalent in the AYAs.
The U.S. Food and Drug Administration (FDA) has recently encouraged the inclusion of 12-17 year olds on disease-and targetappropriate adult oncology trials. 26 An FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology reviewed this age group in 2012 and recommended that adolescent (>12 years) patients be enrolled on trials for adult patients without the need for a previously dedicated pharmacokinetic study in them, 27 a recommendation that has not been enacted. As recently summarized by the FDA, 26 inclusion of adolescents in adult oncology trials will require the cooperation of investigators, cooperative groups, industry, institutional review boards, and regulatory agencies to overcome real and perceived barriers. 26 Despite the FDA Advisory Committee recommendation, the pharmaceutical industry continues to exclude adolescents from their early drug development clinical trials, primarily because of economic disincentives.
It is particularly gratifying to discover that ALL was one of the cancers that benefited from the adolescent accrual increment, but it is disappointing to find that the benefit is sharply limited at the upper end to age 20. A striking AYA ALL accrual cliff that is coincident with an equally striking AYA survival cliff between the ages of 17 and 20
implicates a strong need to increase clinical trial activity in 20-29 year olds with ALL, as well as those with other types of cancers. Until this is accomplished it is likely that the AYA survival gap will persist.
One effort in Ontario, Canada is to specifically study the 15-21 year age interval for determinants of outcome, including access to clinical trials. 28 Another barrier to clinical trials accrual in the AYA years is the referral of patients to centers with, or access to, clinical trials. In Utah, with one children's hospital and one National Comprehensive Cancer
Network center, the referral of patients with cancer to either center dropped from 92% at age 14 to 44% by age 17. [29] [30] [31] [32] [33] [34] [35] By age 20, 2 of every 3 patients stayed in or were referred to private practices and by age 25 less than 30% of the patients were ever seen at the academic medical center. 29 Thus a "referral cliff" also exists in AYA oncology.
Prior reports have quantitated AYA patient with cancer participation in clinical trials in the 2-15% range. 1, 30, 31 Multivariate analysis in one study demonstrated that AYA patients with the same cancer diagnosis common to pediatric and AYA populations who were treated by non-pediatric oncologists were less likely to enroll onto clinical trials. 31 Efforts by the pediatric oncology research community to recruit more AYAs onto clinical trials have been interpreted by some medical oncologists as an attempt to expand the scope of pediatric practice. In reality, the pediatric oncologists' goal is to assist in the provision and conduct of such trials, and in aspects of the care of such patients for which they have more extensive experience than their medical colleagues. If the survival improvement versus treatment trial accrual proportion correlation for ALL (Fig. 3) is generalizable, it may take more than 10% accrual proportion of all available AYA patients to achieve significant survival improvement. On the other hand, once the accrual exceeds 10%, the gain may be strongly correlated with increased participation.
The investigators of the aforementioned study also found that 15 to 19 year-olds had a statistically-significant higher participation rate than any 5-year age range between 20 and 40 years. 31 Also apparent was that clinical trial participation varied directly with the quality of health insurance, with those having no insurance have a statisticallysignificant lower rate of enrollment compared to those with private insurance. 31 The clinical trial participation rate was four times higher by this provision in the ACA (28% vs. 51% reduction) ( Table 1 ). This discrete age-delimited effect indicates that the ACA helped protect this AYA age group from the generalized decline and suggests that the 26-year age cutoff should be increased to an older age. 33 Another line of evidence of the ACA benefit for young AYAs is the observation that uninsured AYAs were less likely to enroll in 2006, before the ACA, but not in 2012/2013 after the ACA was implemented. 34 Many other factors contribute to lack of participation in clinical trials. In addition to economic and insurance-based factors, these can be classified as issues of continuity of care and philosophy, provider bias, patient/family preferences, and cooperative group and cancer center limitations. 35 Recent studies have suggested that effective evidence-based treatment strategies generated in AYA treatment trials may not be rapidly adopted by oncologists. 42 In ALL where the evidence is most abundant, only 31% of AYA patients in the greater San Francisco Bay area received a demonstrably superior pediatric type of regimen during 2008-2012, and the rate declined thereafter to 21%. 42 Adult facilities treating ≥ 2 AYA ALL patients per year captured in the region were statistically significantly more likely to administer a pediatric regimen than lower volume centers, further indicating the importance of referral patterns. 42 Ongoing efforts within NCORP are seeking to further understand factors associated with delayed or limited implementation of effective treatment strategies in AYAs.
Fortunately, NCI-designated cancer centers are evaluating their own AYA referral patterns and clinical trial determinants 43 and intergroup efforts are under way within the current organizational structure of the federal clinical trials enterprise, including the NCTN, to create novel opportunities for collaborative AYA oncology research among the pediatric and adult NCTN groups. 44, 45 Also, a most recent analysis in the United Kingdom documents that sub-groups of AYA patients with advanced solid tumors derive considerable benefit from participating in trials involving novel therapeutics. 46 As also noted in England, however, age-specific biology, pharmacology, proteomics, genomics, clinician and patient behavior studies embedded within clinical trials are required to further improve survival for AYAs. 47 Table 2 is a summary of recommendations that can potentially improve accrual of AYAs to treatment trials. Most of these have been proffered in prior publications and discussed at workshops. [49] [50] [51] [52] [53] [54] It is time to pursue these suggestions more vigorously in order to accomplish
CONCLUSIONS AND RECOMMENDATIONS
in older AYAs what has recently been successful in 15-19 year olds with cancer and in children with cancer before that and in whom virtually all progress emanated from research. As reviewed, many factors
TA B L E 2 Improving treatment trial accrual of AYAs with cancer
Challenge to treatment trial accrual Action to address challenge
Low enrollment in existing clinical trials
• Convince community oncologists of the value of clinical trials and the need to pursue clinical trials on behalf of their AYA patients.
• Encourage providers that provide care to AYAs with first cancer symptoms to refer to centers that offer clinical trials.
• Increase adoption of National Comprehensive Cancer Network guidelines on referral of AYAs with cancer.
• Facilitate open enrollment of open trials through partnerships between cooperative groups and community hospitals.
• Increase AYA organization engagement with patients and patient rights groups to encourage health care providers to participate in clinical trials.
Clinical trial availability
• Incorporate AYA-specific aims into cooperative group trials.
• For cancers with highly favorable treatment, design new clinical trials with a focus on therapy-related toxicities.
• Increase collaboration between pediatric and adult oncologists to design AYA-focused clinical trials for cancers common among this group.
Physician-related barriers
• Establish an accepted standard of care for AYA cancers among pediatric and adult oncologists.
• Increase financial incentives for collaboration between pediatric and adult oncologists.
Institutional barriers
• Increase use of centralized institutional review boards to encourage access and participation in clinical trials.
Societal barriers
• Provide health insurance to all AYAs, not just to those less than 25 years of age who are able to continue on the parents' insurance plan.
• Expand and enforce requirements of the health insurance industry to include coverage of clinical trial costs.
• Empower AYAs to expect their medical providers to discuss clinical trials and arrange contact with clinical trial providers.
contribute to lack of participation of AYA patients with cancer in clinical trials. Yet, other countries have been able to overcome many of the limitations. 55 American AYAs with cancer deserve better.
